Shawn Singh, Vistagen CEO (Jason Koerner/Getty Images for Concordia Summit)
August 7, 2023 02:26 PM EDT
Pharma

Vista­gen's pos­i­tive PhI­II for so­cial anx­i­ety nasal spray push­es stock price up 1,000+%

Zachary Brennan

Senior Editor

San Fran­cis­co-based Vista­gen saw its stock soar more than 1,000% at one point on Mon­day af­ter un­veil­ing pos­i­tive topline re­sults from a Phase III tri­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times